BIOVIE INC. (BIVI) - Dilution Analysis

10-Q filing | 7.5M shares outstanding

10-K filing | 7.5M shares outstanding

8-K filing: BioVie Inc. closed an offering of units and pre-funded units on August 11, 2025, resulting in net proceeds of approximately $10.4 million. ($11.24M proceeds)

S-1/A filing: The company is offering 1,986,754 units (

S-1/A filing: BioVie Inc. is offering 1,456,310 units in a firm commitment underwritten offering, with each Unit consisting of one share of Class A Common Stock and one warrant to purchase one share of Common Stock at an assumed public offering price of $10.30 per Unit. They are also offering 1,456,310 pre-funded units, with each Pre-funded Unit consisting of one pre-funded warrant to purchase one share of Common Stock and one Warrant to purchase one share of Common Stock.

S-1/A filing: BioVie Inc. is offering 1,456,310 units in a firm commitment underwritten offering, with each Unit consisting of (i) one share of Class A Common Stock, and (ii) one warrant to purchase one share of Common Stock at an assumed public offering price of $10.30 per Unit. They are also offering 1,456,310 pre-funded units, with each Pre-funded Unit consisting of (i) one pre-funded warrant to purchase one share of our Common Stock and (ii) one Warrant to purchase one share of Common Stock.

8-K filing: Stock split 1-for-10 | Outstanding: 18,507,218 → 1,850,721

S-1 filing: BioVie Inc. is offering 1,456,310 units and 1,456,310 pre-funded units, each consisting of common stock or pre-funded warrants and warrants to purchase common stock.

10-Q filing | 18.5M shares outstanding

10-Q filing | 18.5M shares outstanding

S-1/A filing: Registration of up to 7,711,613 shares of Class A Common Stock issuable upon exercise of warrants.

S-1 filing: This prospectus relates to the offer and resale of up to 7,711,613 shares of Class A common stock issuable upon the exercise of warrants held by selling stockholders.

10-Q filing | 17.8M shares outstanding

8-K filing: BioVie Inc. entered into a placement agent agreement with ThinkEquity LLC for the issuance and sale of up to 1,146,000 shares of Class A common stock at $2.83 per share, with expected gross proceeds of approximately $3,243,180 before deducting fees. ($3.24M proceeds)

8-K filing: The Company closed a registered direct offering of 1,146,000 shares of Class A common stock at a price of $2.83 per share, resulting in gross proceeds of approximately $3,243,180 before deducting fees and expenses. ($3.24M proceeds)

8-K filing: The Company closed a registered direct offering of 2,667,000 shares of Class A common stock at $2.25 per share and a concurrent private placement of warrants to purchase up to 2,667,000 shares of Common Stock at an exercise price of $2.12 per share, resulting in gross proceeds of approximately $6,000,750. ($6.0M proceeds)

8-K filing: BioVie Inc. entered into a placement agent agreement to issue up to 2,667,000 shares of Class A common stock at $2.25 per share and unregistered warrants to purchase 2,667,000 shares of Common Stock at an exercise price of $2.12 per share, along with a warrant to the Placement Agent to purchase 133,350 shares of Common Stock at $2.8125 per share. ($6.0M proceeds)

8-K filing: BioVie Inc. entered into a placement agent agreement for the issuance and sale of up to 4,443,000 shares of Class A common stock at $1.50 per share and agreed to issue unregistered warrants to purchase 4,443,000 shares of common stock at an exercise price of $1.37 per share in a concurrent private placement. The Company also issued a warrant to the Placement Agent, exercisable to purchase 222,150 shares of Common Stock at an exercise price of $1.875 per share. ($6.66M proceeds)

8-K filing: The company closed a registered direct offering of 4,443,000 shares of Class A common stock at $1.50 per share and a concurrent private placement of warrants to purchase up to 4,443,000 shares of common stock at an exercise price of $1.37 per share, resulting in gross proceeds of approximately $6,664,500. ($6.66M proceeds)

10-K filing | 8.0M shares outstanding

8-K filing: The Company closed a public offering of 1,360,800 shares of Class A common stock, pre-funded warrants to purchase 600,000 shares of Common Stock, and warrants to purchase up to 1,960,800 shares of Common Stock at a combined price of $1.53, generating gross proceeds of approximately $3,000,000 before deducting fees and expenses. ($3.0M proceeds)

8-K filing: BioVie Inc. entered into a placement agent agreement with ThinkEquity LLC for the issuance and sale of up to 1,960,800 shares of class A common stock and/or pre-funded warrants at $1.53 per share and $1.5299 per pre-funded warrant, respectively, along with common stock purchase warrants. ($3.0M proceeds)

8-K filing: Stock split 1-for-10 | Outstanding: 61,018,606 → 6,101,860

10-Q filing | 61.0M shares outstanding

8-K filing: The Company closed a public offering of 15,000,000 shares of Class A common stock, pre-funded warrants to purchase 6,000,000 shares of Common Stock, and warrants to purchase up to 10,500,000 shares of Common Stock at a combined public offering price of $1.00 per share, with gross proceeds of approximately $21 million. ($21.0M proceeds)

8-K filing: BioVie Inc. entered into a placement agent agreement with ThinkEquity LLC for an offering of up to 21,000,000 shares of class A common stock and/or pre-funded warrants, along with common stock purchase warrants, with expected gross proceeds of approximately $21 million before deducting fees and expenses; the offering is expected to close on March 6, 2024. ($21.0M proceeds)

10-Q filing | 38.2M shares outstanding

8-K filing: BioVie Inc. issued 8,136,058 shares of Class A common stock under the Sales Agreement for total net proceeds of $59.4 million after commissions and expenses of approximately $1.8 million as of January 19, 2024. ($59.4M proceeds)

10-Q filing | 36.7M shares outstanding

S-3 filing: This is an S-3 filing for a shelf registration to offer Class A common stock, preferred stock, warrants, debt securities, rights to purchase common stock or other securities, and/or units up to a total dollar amount of $300,000,000, and also covers the resale of up to 311,002 shares of Class A common stock issuable upon the exercise of Lender Warrants by selling stockholders.

10-K filing | 36.8M shares outstanding

10-Q filing | 35.3M shares outstanding

8-K filing: BioVie Inc. reports the issuance of 7,391,228 shares under the Controlled Equity OfferingSM Sales Agreement for net proceeds of $48.8 million as of April 3, 2023, and the termination of B. Riley Securities, Inc.'s role as a sales agent. ($48.8M proceeds)

S-3 filing: This is an S-3 filing for BioVie Inc. covering expenses, indemnification, recent unregistered sales of securities (including common stock and warrants to Acuitas), and exhibits including the underwriting agreement.

10-Q filing | 35.0M shares outstanding

8-K filing: BioVie Inc. issued 3,709,509 shares of Class A common stock under the Controlled Equity OfferingSM Sales Agreement for net proceeds of $29.0 million after commissions and expenses of approximately $898,000. ($29.0M proceeds)

RW filing: BioVie Inc. is withdrawing its Registration Statement on Form S-1 (File No. 333-268313) filed on November 10, 2022, and will not pursue the public offering at this time.

8-K filing: BioVie Inc. increased the aggregate amount of shares of its Class A common stock that may be sold pursuant to the Controlled Equity OfferingSM Sales Agreement from $8.1 million to $17.5 million. ($7.4M proceeds)

S-1 filing: BioVie Inc. is offering shares of Class A common stock.

10-Q filing | 30.5M shares outstanding

10-K filing | 30.2M shares outstanding

8-K filing: BioVie Inc. entered into a securities purchase agreement with Acuitas Group Holdings, LLC to issue and sell 3,636,364 shares of Class A common stock at $1.65 per share and a warrant to purchase 7,272,728 shares at an exercise price of $1.82, for gross proceeds of approximately $6 million. ($6.0M proceeds)

10-Q filing | 25.0M shares outstanding

10-Q filing | 25.0M shares outstanding

10-Q filing | 23.7M shares outstanding

10-K filing | 24.8M shares outstanding

10-Q filing | 13.9M shares outstanding

8-K filing: BioVie Inc. may issue up to 18.0 million shares of its common stock to NeurMedix (or its successor) upon achievement of certain milestones, as per Amendment No. 1 to the Asset Purchase Agreement.

8-K filing: BioVie Inc. acquired certain assets from NeurMedix, Inc. in exchange for 8,361,308 shares of BioVie's common stock and a cash payment estimated at $3.0 million, with potential for future contingent consideration.

10-Q filing | 13.9M shares outstanding

S-3 filing: BioVie Inc. is offering shares of Class A common stock, preferred stock, debt securities, and rights to purchase common stock or other securities for a maximum aggregate offering price of $100,000,000.

S-1/A filing: The company is offering shares of common stock to fund clinical trials of their lead product candidate BIV201 and for working capital and other general corporate purposes.

S-1/A filing: S-1/A filing for an offering of common stock to fund clinical trials of BIV201 and for working capital and other general corporate purposes.

S-1/A filing: This S-1/A filing relates to a company pursuing the discovery, development, and commercialization of innovative drug therapies, primarily focused on BIV201 for the treatment of ascites due to chronic liver cirrhosis, and includes details about a proposed offering of common stock.

S-1/A filing: The company is offering up to 1,538,462 units, each consisting of one share of common stock and one-half warrant, each whole warrant exercisable for one share of common stock. The company intends to use the net proceeds of this offering primarily to fund the Lead-in stage of our planned Phase 2b/3 clinical trial of our lead product candidate BIV201, repay bridge financing extended by our controlling stockholder and for working capital and other general corporate purposes.

10-Q filing | 5.2M shares outstanding